Qucik Links

We provide the most professional products and services, please feel free to call contact us.


Please enter the No. of the stock
Example: 00001


Data delayed at least 15 minutes

IPO Timetable

02325 雲康集團
Listing Date2022/05/18
Listing Price7.890
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    1 lot
  • One Lot Success Rate

Yunkang Group is a medical operation service provider in China offering a full suite of diagnostic testing services for medical institutions with a market share of 3.7% in China’s medical operation service market in terms of revenue in 2020.

Medical operation services primarily relate to diagnostic testing services provided to medical institutions which can be divided into diagnostic outsourcing services and diagnostic testing services for medical institution alliances. It provides such diagnostic testing services to medical institutions in its six independent clinical laboratories and on-site diagnostic centers in medical institutions. It also provides diagnostic testing services to non-medical institutions in China via an outpatient clinic.

Up to April 2022, the Group had assisted in establishing and operating 322 on-site diagnostic centers, serving over 700 medical institutions under its diagnostic testing services for medical institution alliances. Its customers primarily consisted of hospitals, community health clinics and non-medical institutions.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares138.19M shares
No. of International Offer Shares124.37M shares
No. of HK Offer Shares13.82M shares
Offer Price$7.89
Stock Code2325
Sponsor(s)CMB International Capital Limited, SPDB International Capital Limited
Underwriter(s)CMB International Capital Limited, SPDB International Capital Limited, China Merchants Securities (HK) Co., Limited, CCB International Capital Limited, CRIC Securities Company Limited, Futu Securities International (Hong Kong) Limited, Blackwell Global Securities Limited, Livermore Holdings Limited
Application PeriodMay 05 (Thu) - noon, May 11 (Wed)
Price Determination DateMay 11 (Wed)
Result Announcement DateOn or before May 17 (Tue)
Result Announcement DateOn or before May 17 (Tue)
Dealings in Shares commence onMay 18, 2022. (Wed)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$7.89
NAV / share ($)$4.18 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 7.89, the net proceeds raised would be HKD 760.90M, of which
55% : expanding and deepening medical institution alliance network over the next five years
20% : upgrading and enhancing operational capabilities and digitalize testing services
10% : expanding diagnostic capabilities with a focus on developing capabilities in key technologies
5% : potential investment and acquisition opportunities
5% : recruiting and training up talent pool
5% : working capital

Remark: The above information is referenced from the prospectus.